Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Diabetes and the Heart: New Clinical Trials and Recent Recommendations

Author(s): ">Stavroula A. Paschou and Gerasimos Siasos*

Volume 26, Issue 37, 2020

Page: [4685 - 4686] Pages: 2

DOI: 10.2174/138161282637200925102942

Next »
[1]
World Health Organization. Diabetes. Available at: https://www.who.int/news-room/fact-sheets/detail/diabetes
[2]
World Health Organization. Cardiovascular Disease. Available at: https://www.who.int/health-topics/cardiovascular-diseases
[3]
American Diabetes Association. Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42(Suppl. 1 ).
[4]
Zinman B, Wanner C, Lachin JM, et al. EMPA-REGOUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-28.
[5]
Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee. LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med 2016; 375: 311-22.
[6]
Ludvik B, Frias JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 in- hibitors in patients with inadequately con- trolled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2018; 6: 370-81.
[7]
Hernandez AF, Green JB, Janmohamed S, et al. Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392: 1519-29.
[8]
Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2019; 7: 356-67.
[9]
Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 2019; 7: 606-17.
[10]
Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephrop- athy. N Engl J Med 2019; 380: 2295-06.
[11]
Paschou SA, Alexandrides T. A year in type 2 diabetes mellitus: 2018 review based on the Endorama lecture. Hormones (Athens) 2019; 18: 401-8.
[12]
Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323.
[13]
Buse JB, Wexler DJ, Tsapas A. Update To: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43: 487-93.

Rights & Permissions Print Cite
Article Metrics
7
1
© 2024 Bentham Science Publishers | Privacy Policy